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ABSTRACT 
Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by loss of survival motor 
neuron (SMN) protein. While SMN restoration therapies are beneficial, they are not a cure. We 
aimed to identify novel treatments to alleviate muscle pathology combining transcriptomics, 
proteomics and perturbational datasets. This revealed potential drug candidates for repurposing 
in SMA. One of the lead candidates, harmine, was further investigated in cell and animal models, 
improving multiple disease phenotypes, including SMN expression and lifespan. Our work 
highlights the potential of multiple, parallel data driven approaches for development of novel 
treatments for use in combination with SMN restoration therapies. 
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INTRODUCTION 
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder 1 and 
the leading genetic cause of infant mortality 2. The major pathological components of the 
disease are the selective loss of spinal cord alpha motor neurons, progressive muscle 
denervation 3 and skeletal muscle atrophy 4. SMA is caused by mutations in the survival 
motor neuron 1 (SMN1) gene 5. SMN protein is ubiquitously expressed and complete loss 
is lethal 6. However, humans have a near-identical centromeric copy of the SMN1 gene, 
termed SMN2, in which a single nucleotide change (C to T) in exon 7 7 results in the 
exclusion of exon 7 from ~90% of the mature transcript 8. The resulting protein is unstable 
and gets rapidly degraded 9. Patients can have a varying number of SMN2 copies, which 
correlates with disease severity as each SMN2 copy retains the ability to produce ~10% 
of functional full-length (FL) protein 10,11.  
The first SMN restoration treatments, Spinraza™ and Zolgensma, have recently been 
approved by the Food and Drugs Administration (FDA) and the European Medicine 
Agency (EMA). Spinraza™ 12 is an antisense oligonucleotide (ASO) that promotes SMN2 
exon 7 inclusion 13 and is administered by lumbar puncture while Zolgensma delivers 
SMN1 cDNA via an adeno-associated virus 9 14 and is administered intravenously. 
Additional systemically delivered and SMN targeting small molecules are currently being 
explored in clinical trials such as risdiplam 15,16. While these treatments have changed the 
SMA therapeutic landscape, they unfortunately fall short of representing a cure 17–20. 
There is therefore a present need for SMN-independent therapies that could be used in 
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combination with SMN restoration treatments to provide a longer-lasting and more 
effective therapeutic management of SMA pathology in patients 17–19.  
Skeletal muscle pathology is a clear contributor to SMA disease manifestation and 
progression and improving muscle health could have significant benefits for patients 21. 
Here, we used an in-depth, parallel approach combining proteomics, transcriptomics and 
the drug pertubational dataset Connectivity Map (CMap) 22,23 to identify differentially 
expressed (DE) genes and proteins in skeletal muscle of the severe Taiwanese 
Smn-/-;SMN2 SMA mice 24 that could potentially be restored by known and available 
pharmacological compounds. This strategy uncovered several potential therapeutic 
candidates, including harmine, which was further evaluated in cell and animal models, 
showing an ability to restore molecular networks and improve several disease 
phenotypes, including SMN expression and lifespan. Our study highlights the tremendous 
potential of intersecting disease multi-omics with drug perturbational responses to identify 
therapeutic compounds capable of modulating dysfunctional cellular networks to 
ameliorate SMA phenotypes. 
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RESULTS 
Early restoration of Smn in SMA mice restores muscle protein and transcript 
expression. 
We first set out to determine the effect of early SMN restoration on the proteomic and 
transcriptomic profiles of SMA skeletal muscle, with the intent to design therapeutic 
strategies against the genes and proteins that remain unchanged. To do so, the severe 
Taiwanese Smn-/-;SMN2 SMA mouse model 24 received a facial intravenous (IV) injection 
at post-natal day (P) 0 and P2 of the previously described Pip6a-PMO or Pip6a-scrambled 
pharmacological compounds (10 g/g) 25,26. Pip6a is a cell-penetrating peptide (CPP) 
either conjugated to an SMN2 exon 7 inclusion-promoting ASO (PMO) or a scrambled 
ASO 25,26. We harvested the tibialis anterior (TA) from P2 (pre-symptomatic) untreated 
Smn-/-;SMN2 and wild type (WT) mice, P7 (symptomatic) untreated Smn-/-;SMN2 and WT 
mice and P7 Pip6a-scrambled- and Pip6a-PMO-treated Smn-/-;SMN2 mice. TAs were 
then cut in two, whereby one half was used for transcriptomics and the other for 
proteomics. qPCR analysis of the ratio of FL SMN2 over total SMN2 confirms a significant 
increase in FL SMN2 expression in P7 Pip6a-PMO-treated Smn-/-;SMN2 mice compared 
to age-matched untreated and Pip6a-scrambled-treated Smn-/-;SMN2 mice (Fig. 1a).  
Despite differences between transcriptomic and proteomic methodologies highlighted by 
hierarchical clustering and combined Principal Component Analysis (PCA) 
(Supplementary Fig. 1), we were able to find clear separation of experimental groups and 
agreement between transcriptomic and proteomic profiles once the variance attributed to 
the differences in methodologies was removed (Fig. 1b). At P7, we observed clear 
separation of Smn-/-;SMN2- and WT samples, where only P7 Pip6a-PMO treated Smn-/-
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;SMN2- mice clustered with WT. P2 Smn-/-;SMN2 and WT samples cluster together 
suggesting that overt disease cannot be detected in omics readouts at this early stage 
(Fig. 1b, Supplementary Fig. 2). In the PCA of P7 samples only (Fig. 1c for proteomics 
and Fig. 1d for transcriptomics), we noted clustering of P7 Pip6a-PMO-treated 
Smn-/-;SMN2 mice with untreated P7 WT animals, implying full restoration to normal 
phenotypes. Surprisingly, we also detected segregation of Pip6a-scrambled-treated 
samples at both transcriptomics and proteomics levels, revealing that presence of the 
CPP itself impacts transcription and translation (Fig.1 c,d). Importantly, both the combined 
and separate analysis of transcriptomic and proteomic data allowed us to identify a robust 
SMA disease signature in muscle and a Pip6a-PMO treatment efficacy signature. Indeed, 
identification of differentially expressed genes and proteins reveals that early induction of 
FL SMN expression by Pip6a-PMO normalizes the expression of all transcripts and all 
but 11 proteins in the TA of Smn-/-;SMN2 mice (Table 1, Supplementary Table 1). Of note, 
one of the proteins that remained significantly downregulated is Smn itself 
(Supplementary Table 1). 
Our in-depth molecular profiling thus demonstrates for the first time that increasing FL 
SMN2 in neonatal SMA mice quasi-completely normalizes muscle transcripts and 
proteins, highlighting at the molecular level the potential treatment benefits arising from 
early intervention.  
 
CMap perturbational profiles identify potential novel non-SMN treatments  
We used the transcriptomic and proteomic profiles of the Smn-/-;SMN2 mice treated with 
Pip6a-PMO to find drugs that induced similar transcriptional patterns using the 
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Connectivity Map (CMap) resource 27,28. For this, we obtained a cleaned and reversed 
disease signature for both transcriptomics and proteomics data by excluding the genes 
and proteins restored by Pip6a-scrambled (Pip6a-scrambled-treated Smn-/-;SMN2 vs 
untreated WT) from the overlap between disease (untreated Smn-/-;SMN2 vs untreated 
WT) and Pip6a-PMMO (Pip6a-PMO treated Smn-/-;SMN2 vs untreated Smn-/-;SMN2) 
(Fig. 2a). Although these cleaned sets of transcripts and proteins did not show high 
overlap between omics data types (Fig. 2b), we found similarity at the level of enriched 
pathways (Fig. 2c). Individual pathway analysis for the disease and the Pip6a-PMO 
treatment are compiled in Supplementary file 1. The top 10 pharmacological compounds 
from CMap that showed a reversed pattern of expression for the disease signature, and 
similar expression patterns to those observed with Pip6a-PMO treatment are listed in 
Table 2. Importantly, a subset of these drugs, namely salbutamol29 and alsterpaullone30, 
have already been considered for SMA treatment, highlighting the capability of this 
analytic approach to identify relevant therapeutic options for SMA.  
To further validate our approach, we chose to evaluate the potential of harmine 
(chemically akin to harmol), a drug identified by its CMap profile but not previously 
evaluated for SMA, which was present in several proteomic and transcriptomic signatures 
(Table 2). Harmine is an alkaloid isolated from the seeds of Peganum harmala, 
traditionally used for ritual and medicinal preparations 31,32. Harmine has also 
demonstrated therapeutic benefits 33 in animal models of the motor neuron disease 
amyotrophic lateral sclerosis (ALS) 34 and the muscle disorder myotonic dystrophy type 
1 (DM1) 35.  
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We firstly validated the genes and proteins predicted to be dysregulated by the 
transcriptomics and proteomics data and to be normalized by harmine through the CMap 
analysis. We indeed confirm by qPCR analysis that the genes Snrnp27, Gls, Aspm and 
Mcm2 are significantly downregulated while Clpx, Ppm1b, Tob2 and Cdkn1a are 
significantly upregulated in the TA of P7 Smn-/-;SMN2 mice compared to WT animals (Fig. 
3a). We then evaluated the ability of harmine to impact the expression of these genes by 
treating C2C12 myoblasts, NSC-34 neuronal-like cells, SMA patient fibroblasts and 
control fibroblasts with 25, 35 and 50 µM of the drug for 48 hours. We find that harmine 
demonstrates its predicted activity in a cell- and dose-dependent manner (Fig. 3b). Of 
note, harmine also displayed inhibitory effects on proliferation and viability at the higher 
doses in C2C12s and NSC-34s (Supplementary Fig. 3). Finally, we investigated the 
influence of harmine on SMN expression and observe a significant increased Smn 
expression in C2C12s and NSC34s at several doses (Fig. 3c). Interestingly, we also find 
a significant upregulation of FL SMN2 in SMA patient fibroblasts without any changes in 
total SMN2 (Fig. 3d). 
Thus, our strategy of combining transcriptomics, proteomics and drug perturbational 
datasets has resulted in the generation of a list of several drugs with the potential to 
restore muscle health in SMA. Importantly, selecting harmine for additional proof-of-
concept investigations, highlights the strength of this approach. 
 
Administration of harmine to SMA mice ameliorates disease phenotypes 
To further evaluate the therapeutic effects of harmine in vivo, we administered it daily to 
Smn-/-;SMN2 mice and Smn+/-;SMN2 control littermates by gavage (10 mg/kg diluted in 
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0.9% saline) starting at P0. We first evaluated the effects of harmine on the expression 
of Snrnp27, Gls, Aspm, Mcm2, Clpx, Ppm1b, Tob2 and Cdkn1a in muscle (triceps) of P7 
untreated and harmine-treated Smn-/-;SMN2 and Smn+/-;SMN2 mice (Fig. 4a). In vivo, 
harmine only impacted the expressions of Snrnp27 and Tob2 in Smn-/-;SMN2 mice, 
towards normalized levels (Fig. 4a). Similar to that observed in vitro, harmine 
administration significantly increased FL SMN2 expression in Smn-/-;SMN2 mice but not 
total SMN2 (Fig. 4b). Total SMN protein levels were also not affected by harmine (Fig. 
4c).  
We next assessed the effect of harmine upon disease progression and find a significant 
increase in survival of harmine-treated Smn-/-;SMN2 mice compared to untreated Smn-/-
;SMN2 animals (Fig. 4d). Harmine administration also improved weights of treated Smn-
/-;SMN2 mice compared to untreated Smn-/-;SMN2 animals (Fig. 4e). Harmine did not 
impact the weights of Smn+/-;SMN2 control littermates (Fig. 4f). An intermediate SMA 
mouse model, termed Smn2B/- 36, was also treated with harmine. Harmine administration 
to Smn2B/− mice similarly resulted in a significant increase in survival compared to 
untreated Smn2B/− animals (Fig. 4g), albeit to a lesser extent, most likely due to the fact 
that the treated animals developed tremors and needed to be culled. Tremors have 
indeed been reported in animal studies of long-term harmine administration 37–39. 
Nevertheless, harmine significantly increased the weights of treated Smn2B/− mice 
compared to untreated Smn2B/− animals (Fig. 4h). Interestingly, harmine also had a small 
but significant impact on the weights of treated Smn2B/+ control littermates compared to 
untreated Smn2B/+ animals (Fig. 4i).  
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Given that harmine was chosen to target molecular effectors in muscle, we measured the 
myofiber size in the TAs from P7 untreated and harmine-treated Smn-/-;SMN2 and Smn+/-
;SMN2 mice. We observe an increased proportion of larger myofibers in harmine-treated 
Smn-/-;SMN2 mice compared to untreated Smn-/-;SMN2 animals (Fig. 4j). 
Finally, harmine has also been been reported to increase the expression of the 
neuroprotective glutamate transporter 1 (GLT-1) 40,41 and thus, we assessed GLT-1 
protein levels in P7 spinal cords from untreated and harmine-treated Smn-/-;SMN2 and 
Smn+/-;SMN2 mice. We find that GLT-1 levels are significantly lower in untreated Smn-/-
;SMN2 mice compared to untreated Smn+/-;SMN2 animals and that harmine 
administration significantly increases GLT-1 expression in treated Smn-/-;SMN2 mice (Fig. 
4k). 
We thus demonstrate that treating SMA mice with harmine significantly improves multiple 
molecular and pathological phenotypes in both skeletal muscle and the spinal cord. 
 
Harmine administration restores gene expression in muscle of SMA mice 
To systematically explore the effects of harmine in SMA muscle, we performed RNA-
sequencing (RNA-Seq) on TAs from P7 untreated and harmine-treated Smn-/-;SMN2 and 
WT mice. A total of 15,523 protein coding genes were identified across all samples. We 
find that harmine significantly reduces the number of differentially expressed genes in 
Smn-/-;SMN2 when compared to WT animals (Fig. 5a). Interestingly, harmine treatment 
in WT animals influences the expression of significantly fewer genes than in Smn-/-;SMN2 
mice (Fig. 5b). Finally GO analysis with the number of fully (1038) and partially restored 
(574) genes identifies several pathways that are positively impacted by harmine in SMA 
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muscle (Fig. 5c), many of which have been previously implicated in SMA pathology such 
as glucose metabolism 42.  
Our RNA-Seq analysis therefore supports our earlier prediction that harmine could 
reverse some of the molecular pathologies in SMA muscle.  
 
Harmine restores multiple, but not all, molecular networks disturbed in muscle of 
Smn-/-;SMN2 mice 
To assess the restorative effects of harmine, we built a gene functional network from the 
top 500 differentially expressed genes using functional relationships defined by a 
phenotypic linkage network that links genes together that are likely to influence similar 
phenotypes 43. Louvain clustering of this network identified six modules of interconnected 
genes disturbed in Smn-/-;SMN2 mice muscle, of which four (M1, M2, M4 and M5) out of 
six were partially restored by harmine treatment (Fig. 6a). Enrichment analysis in mouse 
phenotypes highlighted several pathways known to be involved in the pathology such as 
lipid and glucose metabolism, muscle fiber morphology and contraction (Fig. 6b) providing 
a molecular explanation for the observed phenotypes in harmine-treated SMA mice and 
a similarity to the pathways associated with Pip6a-PMO treatment (Fig. 2c). Through 
Ingenuity Pathway Analysis (IPA), we identified upstream regulators of the restored gene 
modules (Fig. 6c). The expression of a subset of these upstream regulators was 
evaluated by qPCR in muscle (triceps) of untreated and harmine-treated Smn-/-;SMN2 
and Smn+/-;SMN2 healthy littermates, based on their relevance to muscle health and SMA 
pathology. We find that in control Smn+/-;SMN2 control animals, harmine significantly 
impacted the expression of the dual specificity tyrosine-phosphorylation-regulated kinase 
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1A (Dyrk1a) and myogenic differentiation 1 (Myod1) genes (Fig. 7a). In Smn-/-;SMN2 mice 
however, harmine only affected the expression of Myod1 and in the opposite direction 
(Fig. 7b). To determine if these effects were muscle-specific, we evaluated the expression 
of Dyrk1a and Myod1 in differentiated WT and siRNA Smn-depleted C2C12 cells that 
were either untreated or exposed to 25 or 50 M of harmine for 48 hours. Interestingly, 
we find that harmine significantly reduces Dyrk1a and Myod1 expression in differentiated 
WT C2C12s without any effect in Smn-depleted cells (Fig. 7c,d), revealing differential in 
vivo and in vitro effects of harmine. It is therefore evident that additional mechanistic 
investigations are required to understand the specific and direct benefits of harmine in 
SMA muscle.  
Nevertheless, our bioinformatic analyses uncover several interesting molecular networks 
restored by harmine in SMA muscle that could have further implications for future 
development of muscle-specific therapies for SMA. 
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DISCUSSION  
Despite the tremendous recent advances in SMA gene therapy, this neuromuscular 
disorder remains incurable and there is an urgent need for the development of second-
generation treatments that can be used in combination with SMN-dependent therapies 
17–19. In this study, we therefore evaluated and validated a strategy combining 
transcriptomics, proteomics and drug repositioning to identify novel therapeutic 
compounds that have the potential to improve muscle pathology in SMA. An in-depth 
investigation of one of these drugs, harmine, further supports our approach as harmine 
restored several molecular, behavioural and histological disease phenotypes in both 
cellular and animal models of the disease. 
Of major importance, and to our surprise, we demonstrate that early SMN restoration via 
Pip6-PMO corrects most, if not all, of the transcriptomic and proteomics dysregulations in 
SMA muscle, highlighting the need for and likely benefit from early treatment intervention 
in SMA. It is important to note however that the Pip6a-PMO dose delivered to mice was 
very high and most likely higher than what would be expected in patients. Our pathway 
analyses reveal that many molecular functions that are dysregulated in SMA mice 
compared to WT mice and recovered by Pip6a-PMO have previously been implicated in 
the pathology of SMA such as RNA metabolism and splicing, circadian regulation of gene 
expression, ubiquitin pathways, regulation of Rho protein signal transduction and actin 
binding pathways 44–47. Their normalization following SMN restoration further supports 
their involvement in SMA pathology.  
Using the differentially expressed genes and protein in SMA muscle compared to WT, we 
used a CMap pertubational dataset to provide a list of candidate drugs that could improve 
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SMA pathology, some of which had previously been evaluated in SMA such as 
salbutamol 48. CMap analysis has previously been used to identify new potential 
therapeutics for a range of different conditions such as skeletal muscle atrophy 49, 
osteoarthritic pain 50, osteoporosis 51, gliomas 52, lung adenocarcinoma 53, 
hepatoblastoma 54, acute myeloid leukemia 55 and kidney disease 56. CMap can also help 
establish prediction models for different adverse drug reactions and to evaluate drug 
safety 57.  
In this study, we chose to provide a more in-depth assessment of harmine, a drug 
predicted to restore differentially expressed genes and proteins in SMA muscle. 
Interestingly, one of the genes downregulated in SMA muscle and restored by harmine is 
Snrnp27, a small nuclear RNP (snRNP) involved in pre-mRNA splicing 58 and SMN plays 
a canonical role in the assembly of snRNPs 59. Cyclin dependent kinase inhibitor 1A 
(Cdkn1a or p21) was also identified as a potential molecular target of harmine. This 
mediator of cell cycle and DNA repair is reported to be upregulated in various SMA 
models 60–64. In addition to specific genes, GO analysis of our RNA-Seq data reveals that 
harmine restores several genes implicated in key muscle processes such as muscle 
structure development, muscle contraction, muscle system process and muscle cell 
differentiation. Thus, our combined transcriptomics, proteomics and CMap analysis has 
identified genes that have previously been implicated in SMA pathology. 
While harmine was selected as a non-SMN treatment strategy, we found an upregulation 
of FL SMN2 but not total SMN2 in SMA cells and mice, implying that harmine possibly 
affects alternative splicing of SMN2. Interestingly, harmine restored the alternative 
splicing of TNNT2 and INSR in DM1 myoblasts and muscle from DM1 mice 35, further 
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supporting a role for harmine in modulating mRNA splicing. As demonstrated by our RNA-
Seq analysis, harmine further restores the expression of several genes, indicating that its 
potential benefits may stem from combinatorial effects on SMN and non-SMN genes. The 
latter most likely makes the greatest contribution to the therapeutic benefits observed, 
given that harmine did not increase SMN protein levels. 
In addition, harmine can cross the blood-brain barrier and has well characterized 
neuroprotective properties,  including its ability to upregulate the expression of GLT-1 in 
several neurodegenerative models 40,41. We indeed show that GLT-1 expression is 
reduced in the spinal cord of SMA mice and significantly upregulated following harmine 
administration. Reduced glutamate transporter activity throughout the CNS of SMA 
patients has also been reported 65. The fact that harmine exerts muscle and CNS effects 
makes it an interesting therapeutic option for SMA. However, it is important to note that 
harmine can also exert adverse effects such as the onset of tremors 37–39, which we 
observed when dosing the intermediate Smn2B/- mouse model over a longer period of 
time. 
To our knowledge, this is the first in-depth validation of this combinatorial approach in 
SMA. We are able to show strength and potential of combining multi-omics and drug 
repositioning to uncover novel therapeutic entities, which in this case was aimed at 
improving muscle health in SMA. Our work thus provides an invaluable list of 
pharmacological compounds that can be evaluated for treatment of SMA muscle 
pathology as well as strong support for the use of this combined multi-omics and 
bioinformatic strategy. 
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ONLINE METHODS 
Animals and animal procedures 
Wild-type mice (FVB/N 66 and C57BL/6J 67) were obtained from Jackson Laboratories. 
The severe Smn-/-;SMN2+/- mouse model 68 was also obtained from Jackson Laboratories 
(FVB.Cg-Smn1tm1Hung Tg(SMN2)2Hung/J). The moderate Smn2B/- mouse model 69 was 
generously provided by Dr. Lyndsay M Murray, University of Edinburgh). All experiments 
with live animals were performed at the Biomedical Services Building, University of 
Oxford. Experimental procedures were authorized and approved by the University of 
Oxford ethics committee and UK Home Office (current project license PDFEDC6F0, 
previous project license 30/2907) in accordance with the Animals (Scientific Procedures) 
Act 1986. 
The Pip6a-PMO and Pip6a-scrambled conjugates were both separately prepared in 0.9% 
saline solution and administered at a dose of 10 µg/g via an intravenous facial vein 
injection at P0 and P2.  
Harmine hydrochloride (sc-295136, Insight Biotechnology Ltd, Sante Cruz) was dissolved 
in 0.9% saline and administered daily (10 mg/kg) by gavage.  
 
Synthesis of Pip6a peptide-PMO conjugates 
The PMO sequence targeting ISS-N1 intron 7 (-10-27) (5′-ATTCACTTTCATAATGCTGG-
3′) and scrambled PMO (5’-TAC GTT ATA TCT CGT GAT AC-3’) were purchased from 
Gene Tools LLC (Corvallis).  
The Pip6a Ac-(RXRRBRRXRYQFLIRXRBRXRB)-COOH peptide was manufactured by 
standard 9-fluorenylmethoxy carbonyl chemistry, purified to >90% purity by reverse-
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phase high-performance liquid chromatography (HPLC) and conjugated to the 3’ end of 
the PMO through an amide linkage. The conjugate was purified by cation exchange 
HPLC, desalted and analyzed by mass spectrometry. Pip6a peptide-PMO conjugates 
were dissolved in sterile water and filtered through a 0.22 µm cellulose acetate membrane 
before use. 
 
Laminin staining of skeletal muscle 
Tibialis anterior (TA) muscles were fixed in 4% PFA overnight. Tissues were sectioned 
(13 μm) and incubated in blocking buffer for 2 hours (0.3% Triton-X, 20% FBS and 20% 
normal goat serum in PBS). After blocking, tissues were stained overnight at 4 °C with rat 
anti-laminin (Sigma) in blocking buffer. The next day, tissues were washed in PBS and 
probed using goat-anti-rat IgG 488 secondary antibodies (Invitrogen) for one hour. PBS-
washed tissues were mounted in Fluoromount-G (Southern Biotech). Images were taken 
with a DM IRB microscope (Leica) with a 20× objective. Quantitative assays were 
performed blinded on 3–5 mice for each group and five sections per mouse. The area of 
muscle fiber within designated regions of the TA muscle sections was measured using 
Fiji 70.  
 
qPCR  
RNA was extracted from tissues and cells by either an RNeasy kit from Qiagen or by 
guanidinium thiocyantate-acid-phenol-chloroform extraction using TRIzol Reagent (Life 
Technologies) as per manufacturer’s instructions. The same RNA extraction method was 
employed for similar experiments and equal RNA amounts were used between samples 
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within the same experiments. cDNA was prepared with the High Capacity cDNA Kit (Life 
Technologies) according to the manufacturer’s instructions. The cDNA template was 
amplified on a StepOnePlus Real-Time PCR Thermocycler (Life Technologies) with 
SYBR Green Mastermix from Applied Biosystems. qPCR data was analyzed using the 
StepOne Software v2.3 (Applied Biosystems). Primers used for qPCR were obtained from 
IDT and sequences for primers were either self-designed or ready-made (Supplementary 
Table 2). Relative gene expression was quantified using the Pfaffl method 71 and primer 
efficiencies were calculated with the LinRegPCR software. We normalized relative 
expression level of all tested genes in mouse tissue and cells to RNA polymerase II 
polypeptide J (PolJ) 72 . For human cells, we ran a GeNorm kit (Primer Design) to identify 
RPL13A as a reference/housekeeping gene. Primers for RPL13A were from IDT 
(209604333).  
 
Cell culture 
Both C2C12s 73 and NSC-34s 74 cell lines were maintained in growth media consisting of 
Dulbecco’s Modified Eagle’s Media (DMEM) supplemented with 10% fetal bovine serum 
(FBS) and 1% Penicillin/Streptomycin (all Life Technologies). The cells were cultured at 
37˚C with 5% CO2. C2C12 myoblasts were differentiated in DMEM containing 2% horse 
serum (HS) for 7 days to form multinucleated myotubes.  
For siRNA experiments, C2C12 cells were seeded in 12-well plates and after reaching 
50% confluence, growth media was changed to differentiation media and the cells were 
transfected with 10 µM of siSmn (Duplex name: mm.RiSmn1.13.1) and scrambled siRNA 
(scrambled negative control DsiRNA, #51-01-19-08) (both from IDT) in an siRNA-
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lipofectamine complex (Lipofectamine® RNAiMAX Reagent, Life Technologies). Fresh 
media containing the transfection reagents was changed every 2 days. At D6, the C2C12 
myotubes were further exposed to harmine (25 and 50 µM) for 48 hours. 
Human fibroblasts were obtained from Coriell Institue (SMA GM03813, control AG02261) 
and cultured in DMEM, supplemented with 1% antibiotics/antimycotics and 20% FBS.  
 
MTS assays 
Cell viability and proliferation of C2C12 and NSC-34 cells treated with harmine (sc-
202644, Insight Biotechnology Ltd, Sante Cruz) dissolved in DMSO (final concentration 
0.03%) were evaluated with a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay kit (Colorimetric). The measurements were 
made according to manufacturer’s instructions. Briefly, 10 µl of MTS reagent was added 
directly to the wells and cell plates were incubated at 37°C for a minimum of 1 hour. 
Absorbance was measured at 490 nm on a CLARIOstar® plate reader (BMG LABTECH). 
Background absorbance was first subtracted using a set of wells containing medium only, 
then normalized to and expressed as a relative percentage of the plate-averaged 
untreated control. To chemically induce apoptosis, cells were treated with 10 μM 
Staurosporine (Abcam, Cambridge, UK). 
 
Western blot 
Freshly prepared radioimmunoprecipitation (RIPA) buffer was used to homogenize tissue 
and cells, consisting of 50 mM Tris pH 8.8, 150mM NaCl, 1% NP-40, 0.5% Sodium 
Deoxycholate, 0.1% SDS and complete mini-proteinase inhibitors (1 tablet per 10 ml 
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extraction solution, Roche). Equal amounts of total protein were loaded, as measured by 
Bradford Assay. Protein samples were first diluted 1:1 with Laemmli sample buffer (Bio-
Rad, Hemel Hempstead, UK) containing 5% β-mercaptoethanol (Sigma) and heated at 
100°C for 10 minutes. Next, samples were loaded on freshly made 1.5 mm 12% 
polyacrylamide separating and 5% stacking gel and electrophoresis was performed at 
120 V for ~1.5h in running buffer. Subsequently, proteins were transferred from the gel 
onto to a polyvinylidene fluoride (PVDF) membrane (Merck Millipore) via electroblotting 
at 120 V for 60 minutes in transfer buffer containing 20% methanol. Membranes were 
then incubated for 2h in Odyssey Blocking Buffer (Licor). The membrane was then probed 
overnight at 4°C with primary antibodies (anti-GLT-1, 1:1000, Abcam #ab41621; anti-
SMN, 1:1000, Millipore #MABE230; anti-vinculin, 1:200.000, Sigma #V9131) in Odyssey 
Blocking Buffer and 0.1% Tween-20. The next day, after three 10-minute washing steps 
with PBS, the membrane was incubated for 1 hour at room temperature with secondary 
antibodies conjugated to infrared dyes. Lastly, the membrane was washed again three 
times 10 minutes in PBS and visualized by scanning 700 nm and 800 nm channels on 
the LI-COR Odyssey CLx infrared imaging system (LI-COR) for 2.5 minutes per channel. 
The background was subtracted and signal of protein of interest was divided by signal of 
the housekeeping protein or total protein, per sample.  
 
Proteomic analysis 
Proteomic analyses were performed using a liquid chromatography–mass spectrometry 
(LC-MS)-based method. High-resolution isoelectric focusing (HiRIEF) was used at the 
peptide level in the 3.7–5.0 pH range. Two tandem mass tags (TMTs, chemical labels) 
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were used for mass spectrometry (MS)-based quantification and identification of proteins. 
The data was median normalized based on peptide ratio. Amongst a total of 9798 
potentially detectable proteins, most (8152) were identified in all samples/groups. 
The limma R package was used for differential expression analysis, whereby differentially 
expressed proteins were defined by FDR < 0.05. Gene Ontology enrichment analysis of 
proteomic data was executed using topGO R function and adjusted p values for multiple 
testing following a Benjamini-Hochberg correction. For principal component analysis, we 
used the prcomp R function on the normalized expression data.  
 
Microarray analysis 
RNA was extracted by guanidinium thiocyantate-acid-phenol-chloroform extraction using 
TRIzol Reagent (Life Technologies) as per manufacturer’s instructions. GeneChip Mouse 
Transcriptome Assay 1.0 arrays were used (Affymetrix core facility, Karolinska Institute) 
with 100 ng of RNA per sample. Annotations for the Mouse Transcript Array 1.0 at the 
transcript level were obtained from the Affymetrix website 
(http://www.affymetrix.com/products_services/arrays/specific/mo_trans_assay. 
affx#1_4). We performed background correction and RMA normalization at the probe 
level using oligo R package. We summarized the data in ensemble transcript IDs using 
the average. The total number of ensemble transcript IDs was 93,594, corresponding to 
37,450 genes. For differential expression analysis, we used limma R package and 
considered a transcript differentially expressed if their FDR < 0.05. A gene was 
considered differentially expressed if at least one of the associated transcripts was 
differentially expressed. Gene Ontology enrichment analysis was performed in R using 
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the topGO function as described for proteomic data. For principal component analysis we 
used the prcomp R function on the RMA normalized gene expression data at the gene 
level (for comparison with proteomic data).  
 
Combined analysis of proteomic and transcriptomic data 
To measure the similarity between gene expression profiles, we used the Ward 
hierarchical clustering on the Euclidean distance of 1–r (where r is the Pearson correlation 
between samples). To compare the two omics readouts, proteomic and transcriptomic 
data were scaled (transformed to z-score values), followed by a PCA analysis showing 
that PC1 divides the data at the transcript and protein level (Supplementary Fig. 1). Using 
the kill.pc function in the swamp R package, we extracted a new expression matrix where 
the variance given by PC1 has been removed. Finally, we performed hierarchical 
clustering analysis on the new expression matrix.  
 
RNA-Sequencing analysis 
RNA was extracted using a RNeasy Microarray Tissue Mini Kit from Qiagen. Lysis and 
homogenization were performed using QIAzol Lysis Reagent. cDNA synthesis and RNA-
Seq library construction were performed at the Oxford Genomics Centre (Oxford, United 
Kingdom) using poly(A) enrichment of the mRNA (mRNA-Seq) and HiSeq 4000 Systems 
for sequencing. All samples passed quality control. For differential expression analysis, 
we used DESeq2 on genes expressed across all samples (15523 genes) after removal 
of one outlier (Harmine-treated SMA sample 1). We considered a gene differentially 
expressed at FDR < 0.05. For Gene Ontology enrichment analysis, we used topGO R 
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function and adjusted p values for multiple testing following a Benjamini-Hochberg 
correction. For mouse phenotype enrichment analysis, we downloaded phenotypes from 
the Mouse Genome Database (MGD), Mouse Genome Informatics, The Jackson 
Laboratory, Bar Harbor, Maine (URL: http://www.informatics.jax.org) (June, 2018) and 
used in-house script to correct for the background set of expressed genes.  
 
Gene functional network and clustering method 
A gene functional network is built by extracting interactions from a phenotypic linkage 
network 43 for the top 500 differentially expressed genes between WT and SMA samples. 
To identify modules of highly interconnected genes in the network, we employed 
“cluster_louvain” function in “igraph” R package 75. This function implements the multi-
level modularity optimization algorithm 76,77 where at each step genes are re-assigned to 
modules in a greedy way and the process stops when the modularity does not increase 
in a successive step. 
 
Upstream regulators 
Ingenuity Pathway Analysis (www.qiagenbioinformatics.com) was used to identify the top 
100 upstream regulators for the top 500 differentially expressed genes between WT and 
SMA samples. A reduced list of regulators was identified based on their target genes to 
be within the four harmine-reversed modules. 
 
CMap analysis 
Ensembl transcript ids from mice were mapped to human probe IDs (HG-U133A) using 
biomaRt (Ensembl transcript id mus musculus → Ensembl gene id mus musculus → 
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ortholog_one2one → Ensembl gene id homo sapiens → HG-U133A id). We compared 
the identified disease and Pip6a-PMO signatures (top 500 up-regulated and top 500 
down-regulated genes/proteins) to the drug instances contained in the CMap dataset 
(Build 02, http://www.broadinstitute.org/cmap), which are defined as the basic unit of data 
and metadata in CMap.  
 
Statistical Analysis 
All statistical analyses were done with the most up-to-date Graphpad Prism software. 
When appropriate, a Student’s unpaired two-tail t-test, a one-way ANOVA followed by a 
Tukey’s multiple comparison test or a two-way ANOVA followed by a Sidak’s multiple 
comparison test was used. Outliers were identified via the Grubbs' test. For the Kaplan-
Meier survival analysis, the log-rank test was used and survival curves were considered 
significantly different at p<0.05. 
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FIGURE LEGENDS 
Figure 1. Restoration of protein and transcript expression in skeletal muscle of 
SMA mice following early SMN restoration treatment. Smn-/-;SMN2 mice received a 
facial intravenous injection at postnatal day (P) 0 and P2 of Pip6a-scrambled or Pip6a-
PMO (10  g/g). The tibialis anterior was harvested from P2 untreated Smn-/-;SMN2 and 
WT mice, P7 untreated, Pip6a-scrambled-treated and Pip6a-PMO-treated Smn-/-;SMN2 
mice and P7 untreated WT mice. a. Comparison of the ratio of full length (FL) SMN2 over 
total SMN2 quantified by qPCR between P7 untreated Pip6a-scrambled- and Pip6a-
PMO-treated Smn-/-;SMN2 mice. Data are mean  s.d., n = 4 animals per experimental 
group, one-way ANOVA, ns = not significant, ***p<0.001. b. Heatmap shows the similarity 
between transcriptomic and proteomic expression profiles measured by the Pearson 
correlation between each pair of samples (after the removal of the first principal 
component). c. First two principal components constructed from proteomic profiles mice 
discriminate Smn-/-;SMN2 mice from WT at P7. Notably, only mice treated with Pip6a-
PMO cluster along with WT mice. d. First two principal components based on 
transcriptional profiles of P7 mice show similar clustering of Pip6a-PMO cluster and WT 
mice. 
 
Figure 2. Identification of disease signal reversed by treatment with Pip6a at both 
proteomics and transcriptomics level. a. We retained the proteins (left) and genes 
(right) that were differentially expressed between untreated Smn-/-;SMN2 and WT 
(disease), reversed by treatment with Pip6a and not differentially expressed between 
scrambled-Pip6a treated Smn-/-;SMN2 and WT. We called these as cleaned signatures. 
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b. Overlap of the cleaned signatures between proteins and genes. Although the overlap 
was not high, we detected higher overlaps for genes and proteins with the same 
directionality (both up or both down). c. Enriched GO Biological Processes terms that 
showed similarity across comparisons. The greatest similarity between genes and 
proteins was detected for the cleaned signatures. 
 
Figure. 3. Harmine, as predicted by CMap analyses, is able to reverse the 
expression of genes differentially expressed in SMA muscle in several cellular 
models. a. qPCR analysis of genes predicted to be significantly downregulated (Snrnp27, 
Gls, Aspm and Mcm2) and upregulated (Clpx, Ppm1b, Tob2 and Cdkn1a) in the TA of 
untreated P7 SMA Smn-/-;SMN2 and WT mice. Data are mean  s.d., n = 4 animals per 
experimental group, t test, p = 0.041 (Snrnp27), p = 0.0019 (Gls), p = 0.0001 (Aspm), 
p<0.0001 (Mcm2), p<0.0001 (Clpx), p = 0.0076 (Ppm1b), p = 0.0012 (Tob2), p<0.0001 
(Cdkn1a). b. C2C12s, NSC34s, SMA fibroblasts and control fibroblasts were treated with 
25, 35 of 50 µM of harmine for 48 hours. Expression of Snrnp27, Gls, Aspm, Mcm2, Clpx, 
Ppm1b, Tob2 and Cdkn1a was assessed by qPCR and compared to untreated cells. Data 
are mean  s.d., n = 3 independent wells, two-way ANOVA, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. c. C2C12s and NSC34s were treated with 25, 35 of 50 µM of 
harmine for 48 hours. Expression of Smn was assessed by qPCR and compared to 
untreated cells. Data are mean  s.d., n = 3 independent wells, one-way ANOVA, *p<0.05, 
**p<0.01, ****p<0.0001. d. SMA fibroblasts were treated with 25, 35 of 50 µM of harmine 
for 48 hours. Expression of FL SMN2 and total SMN2 was assessed by qPCR and 
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compared to untreated cells. Data are mean  s.d., n = 3 independent wells, one-way 
ANOVA, ns = not significant, *p<0.05. 
 
Figure 4. Administration of harmine to SMA mice ameliorates several disease 
phenotypes. All treated animals received a daily dose of harmine (10 mg/kg, diluted in 
0.9% saline) by gavage starting at postnatal day (P) 0. a. qPCR analysis of Snrnp27, Gls, 
Aspm, Mcm2, Clpx, Ppm1b, Tob2 and Cdkn1a in triceps of P7 untreated and harmine-
treated Smn-/-;SMN2 mice and Smn+/-;SMN2 control littermates. Data are mean  s.d., n 
= 4 animals per experimental group except for harmine-treated Smn+/-;SMN2 where n = 
3, two-way ANOVA, *p<0.05. b. qPCR analysis of FL SMN2 and total SMN2 in triceps of 
P7 untreated and harmine-treated Smn-/-;SMN2 mice and Smn+/-;SMN2 control 
littermates. Data are mean  s.d., n = 4 animals per experimental group except for 
harmine-treated Smn+/-;SMN2 where n = 3, two-way ANOVA, *p<0.05. c. Western blot 
analysis of SMN protein in triceps of P7 untreated Smn+/-;SMN2 control littermates and 
P7 harmine-treated and untreated Smn-/-;SMN2 mice and. Data are mean  s.d., n = 3 
animals per experimental group, two-way ANOVA, **p<0.01. d. Survival curves of 
untreated and harmine-treated Smn-/-;SMN2 mice. Data are Kaplan Meier survival curve, 
n = 10 for untreated Smn-/-;SMN2 mice, n = 11 for harmine-treated Smn-/-;SMN2 mice, 
Log-rank (Mantel-Cox) test, *p = 0.0211. e. Daily weights of untreated and harmine-
treated Smn-/-;SMN2 mice. Data are mean  s.d., n = 10 for untreated Smn-/-;SMN2 mice, 
n = 11 for harmine-treated Smn-/-;SMN2 mice, two-way ANOVA, ***p<0.001, 
****p<0.0001. f. Daily weights of untreated and harmine-treated Smn+/-;SMN2 mice. Data 
are mean  s.d., n = 13 for untreated Smn+/-;SMN2 mice, n = 15 for harmine-treated 
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Smn+/-;SMN2 mice, two-way ANOVA. g. Survival curves of untreated and harmine-
treated Smn2B/− mice. Data are Kaplan Meier survival curve, n = 9 for untreated Smn2B/− 
mice, n = 7 for harmine-treated Smn2B/− mice, Log-rank (Mantel-Cox) test, *p = 0.0221. h. 
Daily weights of untreated and harmine-treated Smn2B/− mice. Data are mean  s.d., n = 
9 for untreated Smn2B/− mice, n = 7 for harmine-treated Smn2B/− mice, two-way ANOVA, 
*p<0.05, **p<0.01, ****p<0.0001. i. Daily weights of untreated and harmine-treated 
Smn2B/+ mice. Data are mean  s.d., n = 13 for untreated Smn2B/+ mice, n = 8 for harmine-
treated Smn2B/− mice, two-way ANOVA, *p<0.05, **p<0.01. j. Relative frequency of 
myofiber sizes in P7 untreated and harmine-treated Smn-/-;SMN2 and Smn+/-;SMN2 mice. 
Data are percentages, n = 3 animals per experimental group and >400 myofibers per 
experimental group. k. Representative western blots and quantification of Glt-1/vinculin 
expression in the spinal cord of P7 untreated and harmine-treated Smn-/-;SMN2 and 
Smn+/-;SMN2 mice. Data are mean  s.d., n = 3 for untreated and harmine-treated Smn+/-
;SMN2 mice, n = 4 for untreated and harmine-treated Smn-/-;SMN2 mice, two-way 
ANOVA, **p<0.01, ***p<0.001. 
 
Figure 5. RNA sequencing and pathway analysis reveals full rescue of 20% of 
dysregulated genes in SMA muscle following harmine administration. All treated 
animals received a daily dose of harmine (10 mg/kg, diluted in 0.9% saline) by gavage 
starting at postnatal day (P) 0. TAs were harvested at P7 from untreated and harmine-
treated Smn-/-;SMN2 mice and WT animals and processed for RNA sequencing. a. Venn 
diagram representation of the differentially expressed genes based on the negative 
binomial distribution (DESeq2) in untreated Smn-/-;SMN2 mice vs WT mice, harmine-
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treated Smn-/-;SMN2 mice vs WT mice and untreated Smn-/-;SMN2 mice vs harmine-
treated Smn-/-;SMN2 mice. b. Venn diagram representation of the differentially expressed 
genes based on the negative binomial distribution (DESeq2) in untreated Smn-/-;SMN2 
mice vs WT mice, harmine-treated Smn-/-;SMN2 mice vs WT mice and untreated WT mice 
vs harmine-treated WT mice. c. Gene Ontology (GO)/molecular function for fully and 
partly restored genes in muscle of harmine-treated Smn-/-;SMN2 mice. 
 
Figure 6. Identification of molecular effectors involved in harmine activity in SMA 
muscle. a. Gene functional network built on the top 500 differentially expressed genes, 
colored by WT vs SMA (left) and by SMA vs harmine-treated (right). b. Top MGI enriched 
phenotypes for the six identified modules in the network in a. c. Proportions of target 
genes within each of the six modules that are predicted to be regulated by the identified 
upstream regulators by IPA. 
 
Figure 7. Differential in vivo and in vitro effects of harmine on muscle expression 
of predicted molecular effectors. All treated animals received a daily dose of harmine 
(10 mg/kg, diluted in 0.9% saline) by gavage starting at postnatal day (P) 0. a. qPCR 
analysis of Dyrk1A, Sirt1, Pgc1, MyoD1, Pten, Rora and GR expression in triceps of 
P7 untreated and harmine-treated Smn+/-;SMN2 control littermates. Data are mean  s.d., 
n = 4 animals for untreated Smn+/-;SMN2 mice and 3 for harmine-treated Smn+/-;SMN2, 
two-way ANOVA, *p<0.05. b. qPCR analysis of Dyrk1A, Sirt1, Pgc1, MyoD1, Pten, Rora 
and GR expression in triceps of P7 untreated and harmine-treated Smn-/-;SMN2 mice. 
Data are mean  s.d., n = 3 animals for untreated Smn-/-;SMN2 mice and 5 for harmine-
.CC-BY 4.0 International licenseIt is made available under a 
perpetuity.preprint (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for this. http://dx.doi.org/10.1101/2019.12.17.879353doi: bioRxiv preprint first posted online Dec. 18, 2019; 
 30 
treated Smn-/-;SMN2, two-way ANOVA, ***p<0.001. c. qPCR analysis Dyrk1A expression 
in differentiated WT and Smn-depleted C2C12s that were untreated or exposed to 25 or 
50 M harmine. Data are mean  s.d., n = 3 for each experimental group, two-way 
ANOVA, *p<0.05, **p<0.01, ns = not significant. d. qPCR analysis MyoD1 expression in 
differentiated WT and Smn-depleted C2C12s that were untreated or exposed to 25 or 50 
M harmine. Data are mean  s.d., n = 3 for each experimental group, two-way ANOVA, 
**p<0.01, ***p<0.001, ns = not significant. 
 
TABLES 
Table 1. Number of differentially expressed (DE) transcripts and proteins between 
experimental groups. 
Table 2. Top 10 top pharmacological compounds identified by CMap analysis based on 
three expression signatures for both the transcriptomic data and proteomic data.   
 
SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure 1. Clustering and principal component analysis integrating 
proteomic and transcriptomic data. a. Heatmap correspond to the Pearson correlation 
between each pair of proteomic and transcriptomic profiles. Gene expression profiles 
show higher correlations than proteomic data, but similar clustering of experimental 
groups is observed within each type of data. b. Principal component analysis of the 
proteomic and transcriptomic data separates by data by type (RNA or Protein) along the 
first component. 
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Supplementary Figure 2. Principal component analysis on proteomic (a) and 
transcriptomic (b) data of untreated post-natal day (P) 2 and P7 Smn-/-;SMN2 and WT 
mice. 
 
Supplementary Figure 3. In vitro Dose-dependent toxicity of harmine treatment in 
vitro. C2C12s (a) and NSC-34s (b) were treated with 1, 10, 25 or 50 µM for 24, 48 or 72 
hours. Control groups were untreated cells or cells treated with either DMSO (vehicle) or 
Staurosporine (positive control). An MTS assay was performed on all experimental 
groups and MTS scores are normalized to untreated cells at 24 hours (100%). Data are 
mean  s.d., n = 3 independent wells, two-way ANOVA, **p<0.01, ***p<0.001, 
****p<0.0001. 
 
SUPPLEMENTARY TABLES 
Supplementary Table 1. Proteins downregulated in P7 Pip6a-PMO-treated Smn-/-;SMN2 
mice compared to P7 untreated WT mice. 
 
Supplementary Table 2. List of mouse and human qPCR primers. 
 
 
SUPPLEMENTARY FILES 
 
Supplementary File 1. Top biological processes enriched among the genes differentially 
expressed in disease and Pip6a-PMO treatment. 
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